Dry beans inhibit development of mammary cancer

Feb 04, 2009

As the world seeks new ways to prevent and treat chronic diseases such as diabetes, heart disease and cancer, more research continues to be conducted on the benefits of certain foods in reducing people's risk of contracting these ailments. Legumes in particular are often cited as being high in antioxidants, which have the property of being able to fight off free radical cells within the body, reducing the risk of cancer and other chronic diseases. A recent study further investigated these connections, as researchers focused on the benefits of one type of legume, dry beans, in reducing the risk of mammary cancer.

To address whether dry bean consumption is associated with a reduction in mammary cancer, scientists at Colorado State University studied the anticancer activity of six market classes of bean including; small red, great northern, navy, black, dark red and white kidney bean in the diet of laboratory animals. They also evaluated whether the level of antioxidants or seed coat pigments in the bean were related to mammary cancer. The study was funded by a grant from the Beans for Health Alliance, and the Colorado Agricultural Experiment Station with assistance from Archer Daniels Midland Co. and Bush Brothers Inc. Results from the study were published in the January-February 2009 issue of the journal Crop Science.

Cooked dry bean powder from the six market classes and a control group without beans in the diet were fed to laboratory rats in a standard preclinical model for breast cancer. The dry bean powders were also evaluated for antioxidant capacity, phenolic and flavonoid content; all factors thought to be associated with anticancer activity. Chemical analysis of the beans revealed that total phenolic and flavonoid content varied widely among market classes and the differences were strongly associated with seed coat color; where colored beans had ten times or greater phenolic and flavonoid content compared to white beans. Antioxidant capacity of the beans also varied widely among dry bean market classes and were highly related to seed coat color, where colored beans had approximately two to three times greater antioxidant capacity than white beans.

Dry bean consumption from every market class reduced cancer incidence (number of animals with one tumor) and tumor number per animal compared to the control group. Cancer incidence was reduced from 95% in the control group to 67% in animals fed beans. The average number of malignant tumors was also reduced from 3.2 in the control group to 1.4 tumors per animal in the group fed bean. No associations were observed between phenolic content, flavonoid content and antioxidant capacity with cancer among the bean market classes. These results clearly suggest that the anticancer activity in dry bean is not associated with seed color or antioxidant capacity.

Research is ongoing at Colorado State University to investigate the mechanisms and molecules that contribute to the anticancer properties of dry bean. Clinical trials are also underway to determine if bean in the diet of humans are associated with biomarkers for cancer incidence.

Reference: View the abstract at crop.scijournals.org/cgi/content/abstract/49/1/179.

Source: Crop Science Society of America

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

DuPont wins fight for South African seed company

Jul 31, 2013

After a nearly three-year battle with South African regulators, DuPont Co. said Wednesday that it has completed the purchase of a majority stake in South Africa's Pannar Seed. The deal greatly expands the chemical and seed ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

15 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

Hospital volume not linked to costs of cancer surgery

Nov 26, 2014

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.